🇺🇸 FDA

Company profile · Sponsor

CytomX

CytomX Therapeutics

CTMX · NYSE pharma SOUTH SAN FRANCISCO, CA, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

CytomX (CTMX) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker CTMX
Exchange NYSE
Company type pharma
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001501989

Pipeline (8)

Search pipeline →

  1. CX-072

    CytomX

    Solid Tumor

    phase 2 small molecule terminated

    2 trials

  2. CX-2009

    CytomX

    Solid Tumor, Adult

    phase 2 small molecule terminated

    1 trial

  3. CX-2009

    CytomX

    Neoplasms

    phase 2 small molecule completed

    1 trial

  4. CX-2029

    CytomX

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  5. CX-188

    CytomX

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  6. CX-2051

    CytomX

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  7. CX-801

    CytomX

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  8. CX-904

    CytomX

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

Patents (8)

Search patents →

  1. US 12428470

    Compositions containing activatable antibodies

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12139543

    Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12049505

    Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11992528

    Compositions and methods for conjugating activatable antibodies

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11952427

    Anti-CD40 antibodies and uses thereof

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11890354

    Activatable antibodies that bind epidermal growth factor receptor and methods thereof

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11884746

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11867695

    Compositions and methods for detecting protease activity in biological systems

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is CytomX?

CytomX (CTMX) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does CytomX sponsor?

We track 8 ClinicalTrials.gov-linked programs for CytomX, including CX-072 and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does CytomX company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.